Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer-Wyeth Merger Set To Transform China’s Pharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

After Pfizer's announced intention to acquire Wyeth, informed sources reveal that both firms' business and personnel changes in China will start this Q4. Pfizer said the move will strengthen its business and brand name as well as cut expenses. However, nothing is mentioned about the fate of Wyeth's nutritional products - especially milk powder - that make up its main income in the country. Analysts think the merger will not directly impact the local industry since 97 percent of domestic products comprise generic drugs different from Pfizer's product lines. In the short term, these firms can look forward to cloning the giant's about-to-expire patent drugs. Even so, a growing Pfizer will force the local pharmaceutical industry to upgrade and transform itself in the long run. (Click here for more - Chinese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel